IH Life Sciences SRL
The score of IH Life Sciences shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -15 % Total assets +13 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
IH Life Sciences's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 3,459 € | ||||
| Equity | 377,493 € | ||||
| Cash | 35,215 € | ||||
| EBITDA | 24,696 € | ||||
| Total assets | 503,586 € |
Filed annual accounts
- Year ended 30 Sep 2025filed on 30 Apr 2026
- Year ended 30 Sep 2024filed on 07 May 2025
- Year ended 30 Sep 2023filed on 24 Apr 2024
- Year ended 30 Sep 2022filed on 21 Apr 2023
- Year ended 30 Sep 2021filed on 28 Apr 2022
IH Life Sciences's financial analysis
- Solvency75.0%sector median: 75.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of IH Life Sciences
IH Life Sciences's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0687.864.810
- VAT number
- BE0687864810
- Peppol
- Registered · 0208:0687864810 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 12 Jan 2018
- Registered office
- 9240 Zele
- Latest accounts
- 2025 · filed on 30 Apr 2026
- Activity
- Diagnostic imaging services and medical laboratory activities (NACE 86910)
IH Life Sciences (SRL) has been based in Zele since 2018, active in: diagnostic imaging services and medical laboratory activities. For 2025, it reports a net profit of 3,459 € and equity of 377,493 €; its revenue is not published. Its solvency stands at 75.0%, below the median of its sector (75.0%).
Companies similar to IH Life Sciences
Companies in the same business, of comparable size and area, outside its group.
- FICC Business and other management consultancy activities Mortsel · balance sheet 811,784 €
- DR. H. Goethuys Medical specialists activities Genk · balance sheet 907,302 €
- Biomol Business and other management consultancy activities Bernissart · balance sheet €1.84m
- Dokter Martens Chris Medical specialists activities Ledegem · balance sheet 567,171 €
- Medische Beeldvorming Zelzate Diagnostic imaging services and medical laboratory activities Zelzate · balance sheet €1.11m
- Dermpat Medical specialists activities Ghent · balance sheet €1.15m
- SYNLAB Flanders Diagnostic imaging services and medical laboratory activities Berchem-Sainte-Agathe · balance sheet 412,295 €
- Pediatrics Brussels Rental and operating of own or leased real estate Watermael-Boitsfort · balance sheet €1.38m
Frequently asked questions about IH Life Sciences
What is the revenue of IH Life Sciences?
IH Life Sciences files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of IH Life Sciences?
In Belgium, the VAT number is the company number prefixed with BE: BE0687864810 for IH Life Sciences, if the company is VAT-registered. Its company number (CBE) is 0687.864.810.
Where is the registered office of IH Life Sciences?
According to the CBE register, the registered office of IH Life Sciences is in 9240 Zele.
What is the equity of IH Life Sciences?
At the close of the 2025 financial year, the equity of IH Life Sciences amounts to 377,493 €, a solvency of 75.0% of total assets.
Who manages IH Life Sciences?
The register lists 1 active mandates at IH Life Sciences. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of IH Life Sciences
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →